Cimerli

Ranibizumab-eqrn · Sandoz Inc
PRESCRIPTION ONLY (USA)

Cimerli ingredients

Active ingredientStrength
Ranibizumab.3 mg/.05mL, .5 mg/.05mL

What Cimerli is used for

Cimerli is a specialist medicine (vascular endothelial growth factor inhibitor). Its approved uses are listed on the official FDA label below.

Key facts

Brand
Cimerli
Generic name
Ranibizumab-eqrn
Made by
Sandoz Inc
Forms
Injection, Solution
Given
Intravitreal
Drug class
Vascular Endothelial Growth Factor Inhibitor
FDA approval
Biologic licence (BLA) BLA761165
On the US market since
2022

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Cimerli?

Cimerli (Ranibizumab-eqrn) is a specialist medicine made by Sandoz Inc, approved by the US FDA.

What are the ingredients of Cimerli?

Cimerli contains Ranibizumab (.3 mg/.05mL, .5 mg/.05mL).

From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.

← All specialty medicines, USA

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.